Menu
Search
|

Menu

Close
X

miRagen Therapeutics Inc MGEN.OQ (NASDAQ Stock Exchange Capital Market)

4.75 USD
-- (--)
As of Oct 19
chart
Previous Close 4.75
Open --
Volume --
3m Avg Volume 41,501
Today’s High --
Today’s Low --
52 Week High 10.68
52 Week Low 4.40
Shares Outstanding (mil) 30.60
Market Capitalization (mil) 160.94
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.40 Mean rating from 5 analysts

KEY STATS

Revenue (mm, USD)
FY18
7
FY17
4
FY16
3
FY15
3
EPS (USD)
FY18
-0.464
FY17
-1.502
FY16
-27.579
FY15
-21.766
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.14
Price to Sales (TTM)
vs sector
16.44
6.55
Price to Book (MRQ)
vs sector
2.38
4.00
Price to Cash Flow (TTM)
vs sector
--
21.51
Total Debt to Equity (MRQ)
vs sector
14.94
14.15
LT Debt to Equity (MRQ)
vs sector
14.51
11.31
Return on Investment (TTM)
vs sector
-42.31
12.83
Return on Equity (TTM)
vs sector
-46.96
14.95

EXECUTIVE LEADERSHIP

William Marshall
President, Chief Executive Officer, Director, Since 2017
Salary: --
Bonus: --
Jason Leverone
Chief Financial Officer, Treasurer, Secretary, Since 2017
Salary: --
Bonus: --
Paul Rubin
Executive Vice President - Research and Development, Since 2017
Salary: --
Bonus: --
Adam Levy
Chief Business Officer, Since 2017
Salary: --
Bonus: --
Bruce Booth
Director, Since 2017
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

6200 Lookout Rd
BOULDER   CO   80301-3319

Phone: +1303.5315952

Miragen Therapeutics, Inc., formerly Signal Genetics, Inc., is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics with a specific focus on microRNAs and their role in diseases where there is a high unmet medical need. Its clinical product candidate for the treatment of certain cancers, MRG-106, is an inhibitor of microRNA-155 (miR-155), which is found at abnormally high levels in several blood cancers. The Company's clinical product candidate for the treatment of pathological fibrosis, MRG-201, is a replacement for miR-29, which is found at abnormally low levels in a range of pathological fibrotic conditions, including cardiac, renal, hepatic and pulmonary fibrosis, as well as systemic sclerosis. In addition to its clinical programs, it is involved in discovering and developing a pipeline of pre-clinical product candidates. Its pre-clinical product candidates include MRG-107 and MRG-110.

SPONSORED STORIES